British Biotech Firm — with Vital FDA Approval in Hand — to Boost Plymouth Meeting Workforce by 3.5×

Angle, a U.K.-housed biotech firm with its U.S. H.Q. in Plymouth Meeting, is setting to increase its workforce here by more than triple the present payroll. The action, as reported by John George in the Philadelphia Business Journal, comes in response to FDA approval of one of its cornerstone technologies.

The additional hands will be allocated to initiatives that include the company’s Parsortix system. This liquid biopsy technology harvests cancer cells from blood for subsequent analysis. The initial FDA imprimatur has cleared it for use in treating metastatic breast cancer.

Company founder and CEO Andrew Newland said the Montgomery County office, which opened about a year and a half ago, will swell from 15 employees to 50.

“We’ll be hiring more people as we build out the business,” he said.

Newland explained that the company is angling Parsortix toward adoption for use by large-scale medical technology and major pharmaceutical companies.

He cited one of its major advantages: its ability to enable repeat biopsies, allowing treatment plans to be tailored over time.

More of the implications of the Angle corporate plans are in the Philadelphia Business Journal.